Myelofibrosis market will exceed $1 billion by 2025, report

The myelofibrosis market is expected to almost double in value from $545.2 million in 2015 to $1.02 billion by 2025, representing a compound annual growth rate (CAGR) of 6.4%, a new study reveals.

According to research and consulting firm GlobalData’s latest report, the strength of this growth, which covers the seven major markets (7MM) of the USA, France, Germany, Italy, Spain, the UK and Japan, will primarily be driven by the launch of pipeline agents, including Gilead Sciences’ (Nasdaq: GILD) momelotinib, Promedior’s PRM-151, and Johnson & Johnson (NYSE: JNJ)/Geron’s imetelstat. Other factors include an increase in the incidence of myelofibrosis, a chronic blood cancer, and a rise in the use of drugs for the treatment of splenomegaly and constitutional symptoms. [US pharma major Bristol-Myers Squibb (NYSE: BMY) currently has rights to PRM-151 and holds an option to acquire Promedior; Ed.]

James Beggs,  GlobalData’s analyst covering oncology and hematology, explains: “Incyte/Novartis’ [NOVN: VX] Jakafi [ruxolitinib] is currently the only drug approved for the treatment of myelofibrosis-associated splenomegaly and constitutional symptoms in the 7MM. Currently, there are no drugs approved for patients who are refractory or become unresponsive to Jakafi treatment, and momelotinib and imetelstat are expected to contribute towards addressing this issue with launches in the second-line setting in 2017 and 2021, respectively.”